183 related articles for article (PubMed ID: 26001956)
1. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Shai A; Dankort D; Juan J; Green S; McMahon M
Cancer Res; 2015 Aug; 75(15):3167-80. PubMed ID: 26001956
[TBL] [Abstract][Full Text] [Related]
2. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
3. p53 loss does not permit escape from Braf
Garnett S; Dutchak KL; McDonough RV; Dankort D
Oncogene; 2017 Nov; 36(45):6325-6335. PubMed ID: 28745322
[TBL] [Abstract][Full Text] [Related]
4. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M
Genes Dev; 2007 Feb; 21(4):379-84. PubMed ID: 17299132
[TBL] [Abstract][Full Text] [Related]
5. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
6. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.
Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M
Genes Dev; 2014 Mar; 28(6):561-75. PubMed ID: 24589553
[TBL] [Abstract][Full Text] [Related]
7. Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.
González-Sánchez E; Martín-Caballero J; Flores JM; Hernández-Losa J; ; Cortés J; Mares R; Barbacid M; Recio JA
PLoS One; 2013; 8(6):e66933. PubMed ID: 23825589
[TBL] [Abstract][Full Text] [Related]
8. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
9. Early differential responses elicited by BRAF
Bosso G; Lanuza-Gracia P; Piñeiro-Hermida S; Yilmaz M; Serrano R; Blasco MA
Cell Death Dis; 2022 Feb; 13(2):142. PubMed ID: 35145078
[TBL] [Abstract][Full Text] [Related]
10. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.
Luo C; Sheng J; Hu MG; Haluska FG; Cui R; Xu Z; Tsichlis PN; Hu GF; Hinds PW
Cancer Res; 2013 Jul; 73(14):4337-48. PubMed ID: 23650282
[TBL] [Abstract][Full Text] [Related]
11. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
12. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
13. Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.
Strohecker AM; White E
Autophagy; 2014 Feb; 10(2):384-5. PubMed ID: 24362353
[TBL] [Abstract][Full Text] [Related]
14. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
[TBL] [Abstract][Full Text] [Related]
15. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
Huillard E; Hashizume R; Phillips JJ; Griveau A; Ihrie RA; Aoki Y; Nicolaides T; Perry A; Waldman T; McMahon M; Weiss WA; Petritsch C; James CD; Rowitch DH
Proc Natl Acad Sci U S A; 2012 May; 109(22):8710-5. PubMed ID: 22586120
[TBL] [Abstract][Full Text] [Related]
16. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
17. Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF
van Veen JE; Scherzer M; Boshuizen J; Chu M; Liu A; Landman A; Green S; Trejo C; McMahon M
Elife; 2019 Aug; 8():. PubMed ID: 31452510
[TBL] [Abstract][Full Text] [Related]
18. Combined BRAF
Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
[TBL] [Abstract][Full Text] [Related]
19. c-Myc is Required for BRAF
Qu Y; Yang Q; Liu J; Shi B; Ji M; Li G; Hou P
Theranostics; 2017; 7(7):2092-2107. PubMed ID: 28656062
[No Abstract] [Full Text] [Related]
20. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.
Strohecker AM; Guo JY; Karsli-Uzunbas G; Price SM; Chen GJ; Mathew R; McMahon M; White E
Cancer Discov; 2013 Nov; 3(11):1272-85. PubMed ID: 23965987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
